This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Clarkson, T. B. Articles by Wagner, J. D. Search for Related Content PubMed PubMed Citation Articles by Clarkson, T. B. Articles by Wagner, J. D.

A Comparison of Tibolone and Conjugated Equine Estrogens Effects on Coronary Artery Atherosclerosis and Bone Density of Postmenopausal Monkeys

Comparative Medicine Clinical Research Center, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157

Address all correspondence and requests for reprints to: Thomas B. Clarkson, D.V.M., Comparative Medicine Clinical Research Center, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, North Carolina 27157-1040. E-mail: tclarkso{at}wfubmc

Abstract

This study compared the effects of tibolone, a tissue-specific compound for the treatment of climacteric symptoms and the prevention of osteoporosis, with those of conjugated equine estrogens (CEE) with and without medroxyprogesterone (MPA) on bone mineral density and coronary atherosclerosis (CAA) of postmenopausal cynomolgus monkeys. The groups were tibolone [two doses were used, 0.05 mg/kg (LoTib) and 0.2 mg/kg (HiTib)], CEE (0.042 mg/kg), CEE (0.042 mg/kg) plus MPA (0.167 mg/kg given continuously), and a control group given no treatment for 2 yr. Compared with no treatment, bone mineral density was higher by 6.3% (P = 0.0004) in the LoTib group and by 9.5% (P = 0.02) in the HiTib group compared with 4.3% (P = 0.12) for CEE and 4.5% (P = 0.10) for CEE+MPA. Plasma high density lipoprotein cholesterol was reduced by 49% with HiTib and by 34% with LoTib. There were no differences in CAA between control and HiTib (P = 0.60) or LoTib (P = 0.58). CEE and CEE+MPA both reduced CAA by about 62% (CEE vs. control, P = 0.02; CEE+MPA vs. control, P = 0.01). Despite adverse effects of tibolone on plasma lipoprotein concentrations, there was no increase in CAA, suggesting that tibolone is a cardiovascular-safe treatment for climacteric symptoms and the prevention of osteoporosis.

This article has been cited by other articles:

				H. A. M. Verheul, C. J. Timmer, M. L. P. S. van Iersel, L. P. C. Delbressine, and H. J. Kloosterboer Pharmacokinetic Parameters of Tibolone and Metabolites in Plasma, Urine, Feces, and Bile from Ovariectomized Cynomolgus Monkeys after a Single Dose or Multiple Doses of Tibolone Drug Metab. Dispos., July 1, 2007; 35(7): 1112 - 1118. [Abstract] [Full Text] [PDF]

				M. E. Wierman and W. M. Kohrt Review Article: Vascular and Metabolic Effects of Sex Steroids: New Insights Into Clinical Trials Reproductive Sciences, May 1, 2007; 14(4): 300 - 314. [Abstract] [PDF]

				M. L. Bots, G. W. Evans, W. Riley, K. H. McBride, E. D. Paskett, F. A. Helmond, D. E. Grobbee, and for the OPAL Investigators The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on progression of carotid intima-media thickness: the Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study Eur. Heart J., March 2, 2006; 27(6): 746 - 755. [Abstract] [Full Text] [PDF]

				T. B. Clarkson Does tibolone exacerbate atherosclerosis? Eur. Heart J., March 2, 2006; 27(6): 635 - 637. [Full Text] [PDF]

				C. Lemieux, Y. Gelinas, J. Lalonde, F. Labrie, D. Richard, and Y. Deshaies The Selective Estrogen Receptor Modulator Acolbifene Reduces Cholesterolemia Independently of Its Anorectic Action in Control and Cholesterol-Fed Rats J. Nutr., September 1, 2005; 135(9): 2225 - 2229. [Abstract] [Full Text] [PDF]

				K. K. Koh, S. H. Han, M.-S. Shin, J. Y. Ahn, Y. Lee, and E. K. Shin Significant differential effects of lower doses of hormone therapy or tibolone on markers of cardiovascular disease in post-menopausal women: a randomized, double-blind, crossover study Eur. Heart J., July 2, 2005; 26(14): 1362 - 1368. [Abstract] [Full Text] [PDF]

				R. K. Dubey, B. Imthurn, L. C. Zacharia, and E. K. Jackson Hormone Replacement Therapy and Cardiovascular Disease: What Went Wrong and Where Do We Go From Here? Hypertension, December 1, 2004; 44(6): 789 - 795. [Abstract] [Full Text] [PDF]

				M. R. Adams, J. K. Williams, J. R. Kaplan, K. K. Koh, and I. Sakuma Estrogens, Progestins, and Atherosclerosis Arterioscler. Thromb. Vasc. Biol., November 1, 2004; 24(11): e190 - e191. [Full Text] [PDF]

				T. Simoncini, P. Mannella, L. Fornari, A. Caruso, G. Varone, S. Garibaldi, and A. R. Genazzani Tibolone Activates Nitric Oxide Synthesis in Human Endothelial Cells J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4594 - 4600. [Abstract] [Full Text] [PDF]

				K. K. Koh and I. Sakuma Should Progestins Be Blamed for the Failure of Hormone Replacement Therapy to Reduce Cardiovascular Events in Randomized Controlled Trials? Arterioscler. Thromb. Vasc. Biol., July 1, 2004; 24(7): 1171 - 1179. [Abstract] [Full Text] [PDF]

				L. H Kuller Commentary: Hazards of studying women: the oestrogen oestrogen/progesterone dilemma Int. J. Epidemiol., June 1, 2004; 33(3): 459 - 460. [Full Text] [PDF]

				R. K. Dubey, D. G. Gillespie, M. Grogli, H. J. Kloosterboer, and B. Imthurn Tibolone and Its Metabolites Induce Antimitogenesis in Human Coronary Artery Smooth Muscle Cells: Role of Estrogen, Progesterone, and Androgen Receptors J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 852 - 859. [Abstract] [Full Text] [PDF]

				K. K. Koh, J. Y. Ahn, D. K. Jin, B.-K. Yoon, H. S. Kim, D. S. Kim, W. C. Kang, S. H. Han, I. S. Choi, and E. K. Shin Significant Differential Effects of Hormone Therapy or Tibolone on Markers of Cardiovascular Disease in Postmenopausal Women: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study Arterioscler. Thromb. Vasc. Biol., October 1, 2003; 23(10): 1889 - 1894. [Abstract] [Full Text] [PDF]

				L. H. Kuller Hormone Replacement Therapy and Risk of Cardiovascular Disease: Implications of the Results of the Women's Health Initiative Arterioscler. Thromb. Vasc. Biol., January 1, 2003; 23(1): 11 - 16. [Abstract] [Full Text] [PDF]

				T. B. Clarkson, M. S. Anthony, T. S. Mikkola, and R. W. St Clair Comparison of Tibolone and Conjugated Equine Estrogens Effects on Carotid Artery Atherosclerosis of Postmenopausal Monkeys Stroke, November 1, 2002; 33(11): 2700 - 2703. [Abstract] [Full Text] [PDF]

				P. Garnero, C. Jamin, C.-L. Benhamou, C. Pelissier, and C. Roux Effects of tibolone and combined 17{beta}-estradiol and norethisterone acetate on serum C-reactive protein in healthy post-menopausal women: a randomized trial Hum. Reprod., October 1, 2002; 17(10): 2748 - 2753. [Abstract] [Full Text] [PDF]